Genotyping of thrombotic risk factors by MALDI-TOF mass spectrometry

被引:26
作者
Humeny, A
Bonk, T
Berkholz, A
Wildt, L
Becker, CM [1 ]
机构
[1] Univ Erlangen Nurnberg, Inst Biochem, Emil Fischer Zentrum, D-91054 Erlangen, Germany
[2] Univ Erlangen Nurnberg, Klin Frauenheilkunde, D-91054 Erlangen, Germany
关键词
factor V leiden; factor II; genotyping; SNP; mutation; MALDI-TOF;
D O I
10.1016/S0009-9120(01)00264-8
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Objectives: Individual risk of thrombotic disease is highly associated with allelic sequence variations in the blood clotting factor V (F5) and factor II (F2) genes. The polymorphism (G 1691 A) in F5 causing the amino acid substitution R506Q and a genetic variation in the 3' untranslated region of F2 (G20210A) are highly prevalent in the Caucasian population. These findings raise the need for an efficient, cost-effective screening technique. Design and methods: Thrombotic risk alleles were determined by allele specific elongation and termination of extension primers. Primer extension products were analyzed by matrix assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF-MS). Results: Using MALDI-TOF-MS, the polymorphisms F5 (G1691A) and F2 (G20210A) were unequivocally and reliably detectable either alone or in combination (multiplex). Results were confirmed by conventional sequence analysis and, in each case, fully matched data obtained by gel-based genotyping. Conclusions: Due to its accuracy and sensitivity, this procedure can serve as an alternative method for clinical genotyping. It also possesses the potential for high throughput screening.
引用
收藏
页码:531 / 536
页数:6
相关论文
共 18 条
[1]   MUTATION IN BLOOD-COAGULATION FACTOR-V ASSOCIATED WITH RESISTANCE TO ACTIVATED PROTEIN-C [J].
BERTINA, RM ;
KOELEMAN, BPC ;
KOSTER, T ;
ROSENDAAL, FR ;
DIRVEN, RJ ;
DERONDE, H ;
VANDERVELDEN, PA ;
REITSMA, PH .
NATURE, 1994, 369 (6475) :64-67
[2]   MALDI-TOF-MS analysis of protein and DNA [J].
Bonk, T ;
Humeny, A .
NEUROSCIENTIST, 2001, 7 (01) :6-12
[3]   Interaction of coagulation defects and cardiovascular risk factors - Increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A [J].
Doggen, CJM ;
Cats, VM ;
Bertina, RM ;
Rosendaal, FR .
CIRCULATION, 1998, 97 (11) :1037-1041
[4]   Obstetric implications of activated protein C resistance and factor V leiden Mutation [J].
Gherman, RB ;
Goodwin, TM .
OBSTETRICAL & GYNECOLOGICAL SURVEY, 2000, 55 (02) :117-122
[5]  
Hiller E, 1998, Fortschr Med, V116, P26
[6]  
HILLER E, 1998, FORTSCHR MED, V116, P32
[7]  
HILLER E, 1998, FORTSCHR MED, V116, P30
[8]   Thymosin β4 serves as a glutaminyl substrate of transglutaminase.: Labeling with fluorescent dansylcadaverine does not abolish interaction with G-actin [J].
Huff, T ;
Ballweber, E ;
Humeny, A ;
Bonk, T ;
Becker, CM ;
Müller, CSG ;
Mannherz, HG ;
Hannappel, E .
FEBS LETTERS, 1999, 464 (1-2) :14-20
[9]  
Huisman M V, 1999, Curr Opin Hematol, V6, P291, DOI 10.1097/00062752-199909000-00004
[10]  
Page M J, 1998, J Vasc Nurs, V16, P73, DOI 10.1016/S1062-0303(98)90010-3